Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Waters J et al.  
Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial Of Physiotens In Combination) Study

Journal of Clinical and Basic Cardiology 1999; 2 (2): 219-224

PDF    Summary    Figures   

Fig. 1: TOPIC-Studie - Design

Keywords: AmlodipinEnalaprilErstversorgungHydrochlorothiazidHypertonieMoxonidinamlodipineEnalaprilhydrochlorothiazidehypertensionmoxonidineprimary care

The efficacy of moxonidine in the management of essential hypertension was examined in a study conducted in 138 general practice centres in the UK. Slightly more than half of the patients who completed 8 weeks of open-label once-daily moxonidine therapy (294 out of 566) achieved good control of blood pressure (defined as sitting DBP < 90 mmHg or reduction from baseline of at least 10 mmHg) with moxonidine 200 or 400 mcg, administered once daily. The remaining 272 patients were randomized to 4 weeks of double-blind therapy during which they received, in addition to moxonidine 400 mcg o. d., amlodipine 5 mg (n = 87), enalapril 10 mg (n = 88), or hydrochlorothiazide 12.5 mg (n = 97). Satisfactory blood pressure responses were recorded in 46.9 % of patients treated with moxonidine/amlodipine, 26.8 % of patients treated with moxonidine/enalapril and 21.1 % of patients treated with moxonidine/hydrochlorothiazide. The results of this study indicate that moxonidine is effective when used either alone or in combination for the management of essential hypertension in the patient population encountered in UK general practice. Further evaluation of the combination of moxonidine plus amlodipine, which was both effective and well tolerated, is desirable. J Clin Basic Cardiol 1999; 2: 219-24.
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum